MitoImmune Therapeutics Inc. products

MIT platform is a MitoImmune’s proprietary technology that is centered 7-amino indole core structure. MIT compounds based the platform have a unique capability to permeate into negatively charge mitochondrial matrix. The MIT platform inhibits ferroptosis and blocks the DAMPs release and cytokine storm.

Cell death was mainly divided into apoptosis and necrosis, but recent studies have revealed that there are new mechanisms of cell death with biological processes and pathophysiological characteristics besides apoptosis and necrosis. According to the recent recommendation of the Nomenclature Committee of Cell Death, , cell death is divided into apoptosis, autophagy, ferroptosis, pyroptosis, necroptosis, and necrosis, depending on the presence of a molecular mechanism and the release of inflammatory factors. Regulated nectotic cell death including ferroptosis, pyroptosis, and necroptosis causes inflammation by releasing potent pro-inflammatory factors.

The blood-brain barrier (BBB) penetrating technology is essential to develop drugs for neurodegenerative diseases, such as Alzheimer’s, Parkinson’s, ALS, and Huntington’s disease, which have high unmet medical needs. MitoImmune has developed BIM Technology, a central nervous system target technology, and is conducting R&D for the treatment of neurodegenerative disease. BIM Technology is a structure-based multifunctional small-molecule technology that enhances the blood-brain barrier (BBB) permeability and the MIT Platform’s unique function which is mitochondrial-targeting ferroptosis inhibition.